The End of B/Yamagata Influenza Transmission - Transitioning from Quadrivalent Vaccines

N Engl J Med. 2024 Apr 11;390(14):1256-1258. doi: 10.1056/NEJMp2314801. Epub 2024 Feb 28.

Authors

Arnold S Monto¹, Maria Zambon¹, Jerry P Weir¹

Affiliation

¹ From the Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor (A.S.M.); the U.K. Health Security Agency, London (M.Z.); and the Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD (J.P.W.).

PMID: 38416423
DOI: 10.1056/NEJMp2314801

No abstract available

MeSH terms

Antibodies, Viral
Hemagglutination Inhibition Tests
Humans
Influenza A Virus, H3N2 Subtype
Influenza B virus*
Influenza Vaccines* / therapeutic use
Influenza, Human* / prevention & control
Influenza, Human* / transmission
Influenza, Human* / virology
Vaccines, Combined
Vaccines, Inactivated

Substances

Antibodies, Viral
Influenza Vaccines
Vaccines, Combined
Vaccines, Inactivated